Loading...
Market
What will be the market share of patritumab deruxtecan in NSCLC treatments by December 31, 2025?
2
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Industry reports or market analysis from reputable sources
Story
Daiichi Sankyo-Merck's Patritumab Deruxtecan Meets Main Goal in Phase 3 Trial
Sep 17, 2024, 10:04 AM
Daiichi Sankyo and Merck have announced that their cancer drug, patritumab deruxtecan, has met the main goal in a Phase 3 late-stage trial for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The drug, described as a 'guided-missile' cancer treatment, shows promise in targeting specific cancer cells. This development comes as Daiichi Sankyo aims to advance its next generation of targeted oncology drugs, potentially without the need for a partner.
View original story
Similar markets
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%